Last reviewed · How we verify
Ropivacaine 0,375% in SFICB block — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Ropivacaine 0,375% in SFICB block (Ropivacaine 0,375% in SFICB block) — University of Liege.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ropivacaine 0,375% in SFICB block TARGET | Ropivacaine 0,375% in SFICB block | University of Liege | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ropivacaine 0,375% in SFICB block CI watch — RSS
- Ropivacaine 0,375% in SFICB block CI watch — Atom
- Ropivacaine 0,375% in SFICB block CI watch — JSON
- Ropivacaine 0,375% in SFICB block alone — RSS
Cite this brief
Drug Landscape (2026). Ropivacaine 0,375% in SFICB block — Competitive Intelligence Brief. https://druglandscape.com/ci/ropivacaine-0-375-in-sficb-block. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab